Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (10) 10
pde4 inhibitors (9) 9
pharmacology & pharmacy (9) 9
animals (8) 8
asthma (8) 8
humans (8) 8
obstructive pulmonary-disease (8) 8
phosphodiesterase (6) 6
cyclic nucleotide phosphodiesterases, type 4 - metabolism (5) 5
pde4 (5) 5
phosphodiesterase inhibitors - pharmacology (5) 5
pulmonary disease, chronic obstructive - drug therapy (5) 5
randomized clinical-trials (5) 5
amide awd 12-281 (4) 4
anesthesia (4) 4
asthma - drug therapy (4) 4
asthma model (4) 4
chronic obstructive pulmonary disease (4) 4
copd (4) 4
dose-response relationship, drug (4) 4
female (4) 4
inflammation (4) 4
mice (4) 4
pharmacology (4) 4
phosphodiesterase inhibitors - therapeutic use (4) 4
smooth-muscle (4) 4
t-cells (4) 4
airway hyperresponsiveness (3) 3
allergen challenge (3) 3
allergic asthma (3) 3
article (3) 3
asthma - physiopathology (3) 3
binding sites (3) 3
bronchoalveolar lavage fluid (3) 3
cell development (3) 3
cytokine (3) 3
cytokines (3) 3
guinea pigs (3) 3
guinea-pig (3) 3
inflammation - drug therapy (3) 3
male (3) 3
mice, inbred balb c (3) 3
phosphodiesterase inhibitors - adverse effects (3) 3
phosphodiesterase iv (3) 3
respiratory system (3) 3
roflumilast (3) 3
rolipram - pharmacology (3) 3
alcohol (2) 2
allergic mice (2) 2
anti-inflammatory agents - administration & dosage (2) 2
anti-inflammatory agents - adverse effects (2) 2
article subject (2) 2
biological response modifiers (2) 2
brain - enzymology (2) 2
bronchodilation (2) 2
camp (2) 2
camp-specific phosphodiesterase (2) 2
cardiac-muscle (2) 2
cell biology (2) 2
central-nervous-system (2) 2
clinical trials as topic (2) 2
cyclic nucleotide phosphodiesterases, type 1 - antagonists & inhibitors (2) 2
cyclic nucleotide phosphodiesterases, type 4 - chemistry (2) 2
cyclic-nucleotide phosphodiesterase (2) 2
cyclic-nucleotide phosphodiesterases (2) 2
disease models, animal (2) 2
drug evaluation, preclinical (2) 2
enzymes (2) 2
eosinophils (2) 2
health aspects (2) 2
human monocytes (2) 2
immunoglobulin e (2) 2
immunoglobulin g (2) 2
inflammation - physiopathology (2) 2
integrative & complementary medicine (2) 2
interferon (2) 2
interleukin (2) 2
interleukin 4 (2) 2
interleukin 5 (2) 2
isoflavones (2) 2
ketamine (2) 2
leukocytes (2) 2
long-term potentiation (2) 2
lung diseases (2) 2
lymphocytes (2) 2
memory - drug effects (2) 2
methacholine (2) 2
molecular docking simulation (2) 2
necrosis-factor-alpha (2) 2
other systems of medicine (2) 2
ovalbumin (2) 2
phosphodiesterase 4 inhibitors (2) 2
phosphodiesterase 4 inhibitors - chemistry (2) 2
phosphodiesterase 4 inhibitors - pharmacology (2) 2
phosphodiesterase inhibitor (2) 2
phosphodiesterase inhibitors - administration & dosage (2) 2
protein binding (2) 2
protein-kinase (2) 2
pulmonary disease, chronic obstructive - physiopathology (2) 2
research article (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Can the anti‐inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?
by Giembycz, M A
British Journal of Pharmacology, ISSN 0007-1188, 10/2008, Volume 155, Issue 3, pp. 288 - 290
PDE4 inhibitors have been in development as a novel anti‐inflammatory therapy since the 1980s with asthma and chronic obstructive pulmonary disease (COPD)... 
airways inflammation—treatment | PDE4 inhibitors—development status | theophylline | asthma | PDE4/inhaled corticosteroid combination therapy | PDE4 inhibitors—adverse events | PDE4 inhibitors—emetic liability | COPD | PDE4 inhibitors - adverse events | PDE4 inhibitors - development status | Airways inflammation - treatment | PDE4 inhibitors - emetic liability | Theophylline | Asthma | airways inflammation-treatment | EFFICACY | PHARMACOLOGY & PHARMACY | PDE4 inhibitors-emetic liability | PDE4 inhibitors-development status | PDE4 inhibitors-adverse events | Asthma - physiopathology | Phosphodiesterase Inhibitors - adverse effects | Humans | Pulmonary Disease, Chronic Obstructive - physiopathology | Asthma - drug therapy | Dose-Response Relationship, Drug | Phosphodiesterase Inhibitors - administration & dosage | Maximum Tolerated Dose | Anti-Inflammatory Agents - adverse effects | Inflammation - drug therapy | Phosphodiesterase 4 Inhibitors | Anti-Inflammatory Agents - administration & dosage | Inflammation - physiopathology | Pulmonary Disease, Chronic Obstructive - drug therapy | Index Medicus | Commentaries | PDE4 | inhaled corticosteroid combination therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text PDE4 inhibitors: current status
by Spina, D
British Journal of Pharmacology, ISSN 0007-1188, 10/2008, Volume 155, Issue 3, pp. 308 - 315
Phosphodiesterase4 inhibitors are currently under development for the treatment of respiratory diseases including asthma and chronic obstructive pulmonary... 
roflumilast | inflammation | PDE4 | emesis | asthma | cilomilast | COPD | Inflammation | Roflumilast | Cilomilast | Emesis | Asthma | DIFFERENTIAL EXPRESSION | IN-VIVO EFFICACY | NECROSIS-FACTOR-ALPHA | OBSTRUCTIVE PULMONARY-DISEASE | SELECTIVE INHIBITOR | EPITHELIAL-CELLS | INFLAMMATORY CELLS | PHARMACOLOGY & PHARMACY | AIRWAY HYPERRESPONSIVENESS | PHOSPHODIESTERASE TYPE-4 INHIBITOR | ALLERGEN CHALLENGE | Asthma - physiopathology | Phosphodiesterase Inhibitors - adverse effects | Humans | Clinical Trials as Topic | Pulmonary Disease, Chronic Obstructive - physiopathology | Asthma - drug therapy | Dose-Response Relationship, Drug | Phosphodiesterase Inhibitors - administration & dosage | Animals | Anti-Inflammatory Agents - adverse effects | Inflammation - drug therapy | Phosphodiesterase 4 Inhibitors | Anti-Inflammatory Agents - administration & dosage | Drug Evaluation, Preclinical | Inflammation - physiopathology | Pulmonary Disease, Chronic Obstructive - drug therapy | Reviews
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Hesperetin, a selective phosphodiesterase 4 inhibitor, effectively suppresses ovalbumin-induced airway hyperresponsiveness without influencing xylazine/ketamine-induced anesthesia
by Shih, Chung-Hung and Lin, Ling-Hung and Hsu, Hsin-Te and Wang, Kuo-Hsien and Lai, Chi-Yin and Chen, Chien-Ming and Ko, Wun-Chang
Evidence-based Complementary and Alternative Medicine, ISSN 1741-427X, 2012, Volume 2012, pp. 472897 - 10
Hesperetin, a selective phosphodiesterase (PDE) 4 inhibitor, is present in the traditional Chinese medicine, "Chen Pi." Therefore, we were interested in... 
OBSTRUCTIVE PULMONARY-DISEASE | SMOOTH-MUSCLE | INTEGRATIVE & COMPLEMENTARY MEDICINE | ASTHMA MODEL | GUINEA-PIG | RANDOMIZED CLINICAL-TRIALS | AMIDE AWD 12-281 | CELL DEVELOPMENT | ALLERGEN CHALLENGE | T-CELLS | PDE4 INHIBITORS | Interleukin | Immunoglobulin E | Phosphodiesterase IV | Alcohol | Macrophages | Respiratory tract | Interleukin 4 | Interleukin 5 | Lymphocytes | Polyethylene glycol | Bronchoalveolar lavage | Methacholine | Anesthesia | Chronic obstructive pulmonary disease | Alveoli | Phosphodiesterase | Bronchodilation | Enzymes | Ovalbumin | Hesperetin | Cytokines | Immunoregulation | Leukocytes (eosinophilic) | Lung diseases | Bronchus | Traditional Chinese medicine | Leukocytes (neutrophilic) | Pharmacology | Inflammation | Asthma | Herbal medicine | Inhibitors | Ketamine | Lungs | Venom | Obstructive lung disease | Interferon | Eosinophils
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Phosphodiesterase 4 inhibitors and drugs of abuse： current knowledge and therapeutic opportunities
by Christopher M. Olsen Qing-Song Liu
生物学前沿：英文版, ISSN 1674-7984, 2016, Volume 11, Issue 5, pp. 376 - 386
BACKGROUND： Long-term exposure to drugs of abuse causes an upregulation of the cAMP-signaling pathway in the nucleus accumbens and other forebrain regions,... 
药物成瘾 | 抑制剂 | 治疗 | 磷酸二酯酶 | 药物滥用 | 中枢神经系统 | PubMed | 行为模型 | Life Sciences | Biochemistry, general | Genetics and Population Dynamics | VTA | PDE4 | PDE4 inhibitors | Proteomics | Neurobiology | drug addiction | nucleus accumbens | Developmental Biology | Cell Biology | Illegal drugs | Drug abuse | Neurosciences | Health aspects | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Quinolines: a new hope against inflammation
by Mukherjee, Soumita and Pal, Manojit
Drug Discovery Today, ISSN 1359-6446, 04/2013, Volume 18, Issue 7-8, pp. 389 - 398
► Quinoline has emerged as a new pharmacophore for novel anti-inflammatory agents. ► Various quinolines, for example, substituted or fused analogues have been... 
ALPHA CONVERTING-ENZYME | NEUTROPHIL RESPIRATORY BURST | MATRIX-METALLOPROTEINASE INHIBITORS | SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | BIOLOGICAL EVALUATION | ALPHA,BETA-CYCLIC-BETA-BENZAMIDO HYDROXAMIC ACIDS | PHARMACOLOGY & PHARMACY | NECROSIS-FACTOR-ALPHA | HIGHLY POTENT | VANILLOID RECEPTOR-1 ANTAGONISTS | PDE4 INHIBITORS | Inflammation - metabolism | Animals | Cyclooxygenase 2 Inhibitors - pharmacology | Anti-Inflammatory Agents - pharmacology | Inflammation - drug therapy | TRPV Cation Channels - antagonists & inhibitors | Humans | Phosphodiesterase Inhibitors - pharmacology | Cytokines - antagonists & inhibitors | Quinolines - pharmacology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Phosphodiesterase Inhibitors for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease
by Page, Clive P
International Archives of Allergy and Immunology, ISSN 1018-2438, 01/2015, Volume 165, Issue 3, pp. 152 - 164
Xanthines like theophylline have long been recognised as being effective drugs for the treatment of asthma and chronic obstructive pulmonary disease (COPD).... 
Review | Bronchodilation | Anti-inflammatory activity | Chronic obstructive pulmonary disease | Asthma | Phosphodiesterase | SELECTIVE PDE4 INHIBITORS | CAMP-SPECIFIC PHOSPHODIESTERASE | HUMAN NEUTROPHILS | INDUCED INFLAMMATION | IMMUNOLOGY | DIFFERENTIAL REGULATION | HUMAN MONOCYTES | TRANSMEMBRANE CONDUCTANCE REGULATOR | ALLERGY | TNF-ALPHA | HEALTHY-VOLUNTEERS | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE | Bronchodilator Agents - therapeutic use | Theophylline - therapeutic use | Phosphodiesterase Inhibitors - therapeutic use | Humans | Clinical Trials as Topic | Molecular Targeted Therapy | Asthma - drug therapy | Cyclopropanes - therapeutic use | Animals | Benzamides - therapeutic use | Aminopyridines - therapeutic use | Naphthyridines - therapeutic use | Anti-Inflammatory Agents - therapeutic use | Pulmonary Disease, Chronic Obstructive - drug therapy | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Discovery of triazines as potent, selective and orally active PDE4 inhibitors
by Gewald, Rainer and Grunwald, Christian and Egerland, Ute
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 08/2013, Volume 23, Issue 15, pp. 4308 - 4314
Expanding on HTS hit afforded a series of [1,3,5]triazine derivatives as novel PDE4 inhibitors. The SAR development and optimization process with the emphasis... 
Triazine | PDE4 inhibitor | Neutrophilia | Phosphodiesterase | COPD | TARGET | CHEMISTRY, MEDICINAL | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | DRUG DISCOVERY | CHEMISTRY, ORGANIC | CRYSTAL-STRUCTURES | OBSTRUCTIVE PULMONARY-DISEASE | BIOLOGICAL-ACTIVITY | TYPE-4 INHIBITORS | AGENTS | DERIVATIVES | ROFLUMILAST | Protein Structure, Tertiary | Phosphodiesterase 4 Inhibitors - chemistry | Phosphodiesterase 4 Inhibitors - pharmacokinetics | Administration, Oral | Microsomes, Liver - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 7 - metabolism | Half-Life | Rats | Structure-Activity Relationship | Phosphodiesterase 4 Inhibitors - chemical synthesis | Animals | Triazines - chemical synthesis | Triazines - chemistry | Cyclic Nucleotide Phosphodiesterases, Type 7 - antagonists & inhibitors | Molecular Docking Simulation | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Drug Evaluation, Preclinical | Binding Sites | Cyclic Nucleotide Phosphodiesterases, Type 4 - chemistry | Triazines - pharmacokinetics | Physicochemical properties
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)
by Cameron, Ryan T and Coleman, Ryan G and Day, Jon P and Yalla, Krishna C and Houslay, Miles D and Adams, David R and Shoichet, Brian K and Baillie, George S
Biochemical Pharmacology, ISSN 0006-2952, 05/2013, Volume 85, Issue 9, pp. 1297 - 1305
PDE4 is one of eleven known cyclic nucleotide phosphodiesterase families and plays a pivotal role in mediating hydrolytic degradation of the important cyclic... 
Phosphodiesterase inhibitor | Cyclic 3′5′ adenosine monophosphate (cAMP) | Protein kinase A (PKA), PDE4 | Catechol ether | cAMP | Cyclic 3′5′ adenosine monophosphate | TARGET | ACTIVATION | PHOSPHORYLATION | PROTEIN-KINASE | RECEPTOR | OBSTRUCTIVE PULMONARY-DISEASE | Cyclic 3 ' 5 ' adenosine monophosphate (cAMP) | DRUGS | CHEMISTRY | PHARMACOLOGY & PHARMACY | ROFLUMILAST | CONVERTING-ENZYME | Tetrahydroisoquinolines - pharmacology | Catalytic Domain | Phosphodiesterase 4 Inhibitors - chemistry | Phosphorylation | Isoenzymes - genetics | Humans | Isoenzymes - chemistry | Cyclic Nucleotide Phosphodiesterases, Type 4 - genetics | Phosphodiesterase 4 Inhibitors - pharmacology | HSP20 Heat-Shock Proteins - metabolism | Tetrahydroisoquinolines - chemistry | Isoenzymes - metabolism | Computer Simulation | HEK293 Cells | Protein Binding | Molecular Docking Simulation | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Cyclic AMP - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - chemistry
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Ayanin, a non-selective phosphodiesterase 1–4 inhibitor, effectively suppresses ovalbumin-induced airway hyperresponsiveness without affecting xylazine/ketamine-induced anesthesia
by Lee, Fei-Peng and Shih, Chwen-Ming and Shen, Hsin-Yi and Chen, Chi-Ming and Chen, Chien-Ming and Ko, Wun-Chang
European Journal of Pharmacology, ISSN 0014-2999, 2010, Volume 635, Issue 1, pp. 198 - 203
In recent reports, the IC value of ayanin (quercetin-3,7,4′- -trimethylether) was 2.2 μM for inhibiting interleukin (IL)-4 production from purified basophils,... 
Phosphodiesterase inhibitor | Allergic asthma | Ayanin | PDE4 H/PDE4 L ratio | Cytokine | Airway hyperresponsiveness | PDE4 | ratio | ASTHMA MODEL | PDE4(H)/PDE4(L) ratio | RANDOMIZED CLINICAL-TRIALS | AMIDE AWD 12-281 | CELL DEVELOPMENT | PDE4 INHIBITORS | OBSTRUCTIVE PULMONARY-DISEASE | SMOOTH-MUSCLE | B-CELL | ALLERGIC MICE | PHARMACOLOGY & PHARMACY | T-CELLS | Bronchoalveolar Lavage Fluid | Respiratory System - pathology | Inflammation - pathology | Phosphodiesterase Inhibitors - therapeutic use | Immunoglobulin G - blood | Hypersensitivity - drug therapy | Flavonoids - therapeutic use | Immunoglobulin E - blood | Hypersensitivity - metabolism | Hypersensitivity - etiology | Xylazine - pharmacology | Anesthesia | Female | Flavonoids - pharmacology | Phosphoric Diester Hydrolases - metabolism | Cytokines - metabolism | Immunoglobulin E - metabolism | Phosphodiesterase Inhibitors - pharmacology | Ovalbumin - pharmacology | Asthma - drug therapy | Animals | Respiratory System - metabolism | Respiratory System - drug effects | Mice | Mice, Inbred BALB C | Ketamine - pharmacology | Hypersensitivity - blood | Immunoglobulin G - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Genistein, a competitive PDE1–4 inhibitor, may bind on high-affinity rolipram binding sites of brain cell membranes and then induce gastrointestinal adverse effects
by Shih, Chung-Hong and Lin, Ling-Hung and Lai, Ya-Hsin and Lai, Chi-Yin and Han, Cheng-Ying and Chen, Chien-Ming and Ko, Wun-Chang
European Journal of Pharmacology, ISSN 0014-2999, 2010, Volume 643, Issue 1, pp. 113 - 120
The affinities of genistein on phosphodiesterase (PDE)1–4 and cause of gastrointestinal adverse effects of genistein remain unclear. Female BALB/c mice were... 
Allergic asthma | High-affinity rolipram binding site | Phosphodiesterase isozymes 1–4 inhibition | Genistein | Cytokine | Gastrointestinal adverse effect | Phosphodiesterase isozymes 1-4 inhibition | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | TYROSINE KINASE | PROTEIN-KINASE | CARDIAC-MUSCLE | GUINEA-PIG | PDE4 INHIBITORS | IN-VITRO | SELECTIVE INHIBITORS | ASTHMA | PHARMACOLOGY & PHARMACY | T-CELLS | Phosphodiesterase Inhibitors - therapeutic use | Phosphodiesterase Inhibitors - adverse effects | Brain - enzymology | Male | Dose-Response Relationship, Drug | Cyclic Nucleotide Phosphodiesterases, Type 1 - antagonists & inhibitors | Respiratory Hypersensitivity - drug therapy | Anesthesia | Female | Genistein - therapeutic use | Radioligand Assay | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Rolipram - pharmacology | Binding Sites | Cell Membrane - drug effects | Disease Models, Animal | Genistein - adverse effects | Binding, Competitive | Guinea Pigs | Phosphodiesterase Inhibitors - pharmacology | Gastrointestinal Tract - drug effects | Respiratory Hypersensitivity - immunology | Brain - drug effects | Cell Membrane - enzymology | Animals | Genistein - pharmacology | Protein Binding | Mice | Mice, Inbred BALB C | Medical colleges | Complications and side effects | Lung diseases, Obstructive | Isoenzymes | Albumin | Cell membranes | Chemical properties | Angiogenesis inhibitors | Biological response modifiers | Isoflavones
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Improving memory: A role for phosphodiesterases
by Blokland, A and Schreiber, Rudy and Prickaerts, J
Current Pharmaceutical Design, ISSN 1381-6128, 07/2006, Volume 12, Issue 20, pp. 2511 - 2523
During the last decennia, our understanding of the neurobiological processes underlying learning and memory has continuously improved, leading to the... 
cGMP | Short-term storage | Neurotransmitters | Sildenafil | Long-term potentiation(LTP) | PDE4 Inhibitors | OBJECT RECOGNITION MEMORY | ALZHEIMERS-DISEASE | CGMP-DEGRADING PHOSPHODIESTERASE | NITRIC-OXIDE | DEPENDENT PROTEIN-KINASE | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | LONG-TERM POTENTIATION | RAT-BRAIN | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE | SOLUBLE GUANYLATE-CYCLASE | Cyclic AMP - physiology | Memory - drug effects | Neurotransmitter Agents | Humans | Brain - enzymology | Phosphodiesterase Inhibitors - pharmacology | Phosphoric Diester Hydrolases - physiology | Memory - physiology
Journal Article
Details down arrow
12. Full Text PDE4 as a target for cognition enhancement
by Richter, Wito and Menniti, Frank S and Zhang, Han-Ting and Conti, Marco
Expert Opinion on Therapeutic Targets, ISSN 1472-8222, 09/2013, Volume 17, Issue 9, pp. 1011 - 1027
Introduction: The second messengers cAMP and cGMP mediate fundamental aspects of brain function relevant to memory, learning, and cognitive functions.... 
memory | Rolipram | cognition | PDE4 | phosphodiesterase | schizophrenia | cAMP | cyclic nucleotide | Alzheimer's disease | Memory | Cyclic nucleotide | Schizophrenia | Cognition | CAMP | Phosphodiesterase | PROTEIN-KINASE-A | CAMP-SPECIFIC PHOSPHODIESTERASE | INHIBITOR ROLIPRAM | RANDOMIZED CLINICAL-TRIALS | BRAIN DRUG-DELIVERY | AMP-SPECIFIC PHOSPHODIESTERASES | PHOSPHATIDIC-ACID BINDING | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | LONG-TERM POTENTIATION | VARIANT MESSENGER-RNAS | Memory - drug effects | Animals | Cognition - drug effects | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Phosphodiesterase 4 Inhibitors - pharmacology | Humans | Alzheimer’s disease
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Hesperetin-7,3′-O-dimethylether selectively inhibits phosphodiesterase 4 and effectively suppresses ovalbumin-induced airway hyperresponsiveness with a high therapeutic ratio
by Yang, You-Lan and Hsu, Hsin-Te and Wang, Kuo-Hsien and Han, Cheng-Ying and Chen, Chien-Ming and Chen, Chi-Ming and Ko, Wun-Chang
Journal of Biomedical Science, ISSN 1021-7770, 2011, Volume 18, Issue 1, pp. 84 - 84
Background: Hesperetin was reported to selectively inhibit phosphodiesterase 4 (PDE4). While hesperetin-7,3'-Odimethylether (HDME) is a synthetic liposoluble... 
cytokine | hesperetin-7,3'-O-dimethylether | allergic asthma | phosphodiesterase-4 inhibitor | Airway hyperresponsiveness | chronic obstructive pulmonary disease | MEDICINE, RESEARCH & EXPERIMENTAL | ASTHMA MODEL | CARDIAC-MUSCLE | GUINEA-PIG | RANDOMIZED CLINICAL-TRIALS | AMIDE AWD 12-281 | CELL DEVELOPMENT | PDE4 INHIBITORS | CELL BIOLOGY | OBSTRUCTIVE PULMONARY-DISEASE | SMOOTH-MUSCLE | hesperetin-7,3 '-O-dimethylether | ALLERGEN CHALLENGE | Bronchoalveolar Lavage Fluid | Guinea Pigs | Asthma - physiopathology | Ovalbumin - immunology | Bronchial Hyperreactivity - drug therapy | Cytokines - analysis | Cyclic Nucleotide Phosphodiesterases, Type 1 - metabolism | Male | Immunoglobulins - analysis | Blood Cell Count | Cyclic Nucleotide Phosphodiesterases, Type 1 - antagonists & inhibitors | Animals | Phosphodiesterase 4 Inhibitors - administration & dosage | Hesperidin - administration & dosage | Female | Hesperidin - analogs & derivatives | Mice | Mice, Inbred BALB C | Cyclic Nucleotide Phosphodiesterases, Type 3 - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Rolipram - pharmacology | Binding Sites | Disease Models, Animal | Pulmonary Disease, Chronic Obstructive - drug therapy | Cytokines | Biological response modifiers | Health aspects | Immunoglobulin G | Enzyme-linked immunosorbent assay | Asthma | Respiratory therapy | Medicine | Chinese medicine | Nuclear magnetic resonance--NMR | Hospitals | Lymphocytes | Rodents | Mortality | Fluorides | Kinases | Binding sites
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights